Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from managed care entities. Such organizations are frequently erecting barriers to reimbursement, such as steep cost restrictions and approval processes that limit patient access.… Read More